Emerging evidence · Grade B
Sermorelin
Sermorelin Acetate
Score
68 / 100
Half-life
~10–20 min
Status
Compounded
Was FDA
1997 (Geref)
TL;DR
01
The first 29 amino acids of GHRH — a short-acting analog that prompts the pituitary to release its own growth hormone. It was FDA-approved in 1997 (as Geref) for diagnosing growth-hormone deficiency in children, but the brand was discontinued around 2008.
02
Today it exists mainly as a compounded product marketed off-label for adult 'GH optimization' and anti-aging — a use it was never approved for and that lacks controlled-trial support.
03
The best human data for that use is a small 1997 study in older men: six weeks raised nighttime GH and helped a couple of strength measures, but produced no change in body composition, fat, or weight.
04
Its half-life is only about 10–20 minutes, so effects are brief and pulsatile — closer to a gentle nudge than a sustained lever.
05
Because it is now compounded rather than a standardized approved product, purity and dosing consistency are not guaranteed.
Historical approval
Pediatric GHD
Geref, 1997 · discontinued ~2008
Nocturnal GH (elderly, 6 wk)
Increased
Metabolism 1997
Body composition change
None
no DEXA/fat/weight change · 1997
Anti-aging RCTs
None
marketed use is unstudied
Current form
Compounded
no standardized product
Part 01 · How it works
Mechanism.
Sermorelin is the active fragment of GHRH — the hormone that signals the pituitary to release growth hormone. Like tesamorelin, it works by amplifying the body's own GH pulses rather than adding hormone from outside. But it is a shorter, quickly-cleared molecule, so each dose produces a brief bump in GH rather than a sustained rise. The theory behind its anti-aging marketing is that restoring youthful GH pulses could improve body composition — a theory the limited human data has not borne out.
A brief tap on the body's growth-hormone accelerator — the pulse it creates fades within the hour, unlike the longer-acting GHRH analogs.
GHRH(1-29) agonism
The minimal biologically active GHRH fragment; agonist at the pituitary GHRH receptor.
Pulsatile, short-acting
~10–20 min half-life produces a brief GH pulse; typically dosed at night to mimic physiology.
Ceiling by feedback
GH release remains under somatostatin negative feedback, limiting supraphysiologic spikes.
Historical indication
Approved for pediatric GH-deficiency diagnosis/treatment; adult anti-aging use is off-label.
Part 02 · Dosing & administration
How it's taken.
Clinical · trial-validatedValues below describe how Sermorelin has been administered in human clinical trials and/or approved labeling. Provided for educational purposes only — this is not medical advice and not instructions for self-administration. Consult your healthcare provider before making any health decision.
Standard dose
100-300 mcg
Subcutaneous injection · Once daily at bedtime
Duration
3–6 month course
·
Bedtime dosing exploits the natural nocturnal GH pulse (half-life ~10–20 min).
·
Sermorelin has real FDA pedigree (Geref, approved for pediatric GHD) and human data — but the displayed adult "anti-aging" dose is off-label and compounded (Geref discontinued ~2008 for commercial reasons, not safety).
·
No FDA-approved adult regimen exists; compounded dosing varies by pharmacy and is not standardized like the former branded drug.
Need help with reconstitution?
Use the free peptide calculator for dilution, unit conversion, and injection volume.
Part 03 · Safety
Side effects, rare serious events, who shouldn't.
Common
Injection-site reactions
Redness, pain, or swelling at the site.
Common
Flushing / headache
Transient, generally mild.
Occasional
Dysgeusia
Altered taste reported historically.
Occasional
Serious · rare
GH-axis effects
Fluid retention, arthralgia, and glucose effects are possible if GH is meaningfully raised.
Dose-related
IGF-1 / mitogenic caution
Any sustained GH/IGF-1 elevation carries the class mitogenic caution; magnitude with short-acting sermorelin is modest.
Theoretical
Product-quality risk
Unregulated compounded product may not match labeled potency/purity.
Compounding-dependent
Absolute · do not use
×
Active malignancy or history of cancer
×
Pituitary tumor or hypothalamic disorders
×
Diabetic retinopathy
×
Pregnancy or breastfeeding
×
Children under 18 (unless for diagnosed GH deficiency under specialist care)
×
Known hypersensitivity to sermorelin or any component
×
Obesity secondary to hypothalamic lesions
Relative · discuss first
!
Active malignancy — GH/IGF-1 mitogenic caution
!
Pregnancy or breastfeeding — no adequate data
!
Disruption of the hypothalamic-pituitary axis — reduced or absent response
!
Anyone expecting body-composition results — the human data does not support it
Interactions
Insulin
GH secretagogues can increase insulin resistance; may require insulin dose adjustment
Major
Oral hypoglycemics
GH elevation may counteract glucose-lowering effects; monitor blood glucose
Moderate
Corticosteroids
Chronic corticosteroid use blunts GH release and may reduce sermorelin efficacy; concurrent glucocorticoids may suppress response
Moderate
Thyroid hormone replacement
GH can increase T4 to T3 conversion; thyroid levels may need reassessment
Moderate
Somatostatin analogs (octreotide)
Directly antagonizes GHRH-stimulated GH release
Major
Labs to monitor
IGF-1
Baseline, 4 weeks, then every 3 months
Monitor growth hormone axis stimulation
Fasting Glucose & Insulin
Baseline and every 3 months
GH can impair insulin sensitivity
CMP (Comprehensive Metabolic Panel)
Baseline and every 3 months
Liver and kidney function
Thyroid Panel (TSH, Free T4)
Baseline and every 6 months
GH axis can affect thyroid function
HbA1c
Baseline and every 3 months
Track glycemic effects
Part 04 · Evidence
How strong is the evidence?
68
Grade B
Grade B, downgraded from the library's earlier 'Strong' rating. Sermorelin has genuine historical evidence for pediatric GH-deficiency, but its actual modern use — adult anti-aging — is essentially unstudied, and the small human data that exists is negative on body composition.
Mechanistic plausibility
Well-established GHRH biology; restoring GH pulses is a coherent rationale.
80
Human evidence
Solid for the old pediatric-GHD indication; thin and largely negative for the anti-aging use it is now sold for.
58
Safety & tolerability
Long historical use with a benign short-term profile; GH-axis cautions apply.
74
Durability
Short-acting; no evidence of durable body-composition benefit.
60
Independence
Older independent studies exist; modern compounded use is unstudied and unregulated.
66
Part 05 · Research log
Every study we cite.
We list each study with its methodology, funding source, and our quality grade. Flagged studies aren't dismissed — they're tagged so you can weigh them.
01
1997
Metabolism Flagged
Nightly GHRH(1-29) in healthy elderly men
Raised mean nocturnal GH and improved 2 of 6 strength measures, but produced no change in body composition, DEXA fat/muscle, weight, glucose, or lipids.
Open-label, 6 wk, before/after · n = 11 · Small uncontrolled study; the key negative finding is the absence of body-composition change.
PMID 9005976 ↗
Low-Moderate
02
1997
J Clin Endocrinol Metab Flagged
Sermorelin in the diagnosis/treatment of pediatric GH deficiency
Supported sermorelin's approved role in evaluating and treating childhood GH deficiency (the basis for the 1997 FDA approval).
Clinical studies supporting the original approval · Evidence pertains to pediatric GHD, not adult anti-aging use.
PMID 9390775 ↗
Moderate
Evidence against
What didn't work, and where the evidence is thin.
Every publication is incentivized to tell you a peptide works. We catalogue the null results, failed trials, and mechanism limits we found in the same literature — so you can weigh them against the upside, with your provider.
01
The anti-aging use is unstudied — and negative on body composition where tested
Null result Metabolism · 1997
In the main human study relevant to anti-aging use, six weeks of nightly sermorelin raised GH but did not change body composition, fat mass, muscle mass by DEXA, or weight in older men.
What this means: The central promise of the compounded market — improved body composition — is exactly what the available human data failed to show. There are no modern RCTs supporting the marketed use.
PMID 9005976 ↗
02
No standardized product; compounded and unregulated
Mechanism limit Regulatory status · 2026
The FDA-approved brand (Geref) was discontinued around 2008. Current sermorelin is compounded, so potency, purity, and dosing consistency are not guaranteed and not FDA-verified.
What this means: Beyond the thin efficacy evidence, buyers of compounded sermorelin cannot assume the product matches label — a quality-control gap on top of the evidence gap.
Part 06 · Cost & access
Where it's available, at what price.
United States
Compounded (off-label)
No standardized FDA-approved product; available only via compounding pharmacies, typically marketed for off-label 'GH optimization.'
Varies by compounding pharmacy
European Union
Not marketed
No routine approved product.
N/A
United Kingdom
Not marketed
No routine approved product.
N/A
Canada
Not marketed
No routine approved product.
N/A
The Peptide Column takes no affiliate commission from any source. Sermorelin is no longer sold as an FDA-approved product; current supply is compounded and its marketed anti-aging use is off-label and unstudied. We link only to clinician-directed care, never to sellers.
Part 07 · Your appointment
Questions to bring.
01
What are my current IGF-1 levels and do I have a clinical indication for GH stimulation?
02
How does sermorelin compare to direct GH therapy for my situation?
03
What monitoring (IGF-1, blood glucose, etc.) is needed during treatment?
04
What is the appropriate dosing protocol and expected timeline for results?
References
Every citation, numbered.
Citation list. For our editorial read of each study — including bias flags and quality grades — see the Research log above.
- 01.
- 02. Sermorelin in the diagnosis/treatment of pediatric GH deficiency · J Clin Endocrinol Metab, 1997 · PMID 9390775 ↗
- 03.